MedTrace Logo

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head

NCT05706909 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2026-04-17

No results posted yet for this study

Summary

The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.

Conditions

  • Avascular Necrosis
  • Osteonecrosis

Interventions

DEVICE

Genex with ABMC

Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure

Sponsors & Collaborators

  • Biocomposites Ltd

    collaborator INDUSTRY

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Nicolas Piuzzi · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05706909 on ClinicalTrials.gov